Results 101 to 110 of about 16,411 (192)

Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism [PDF]

, 2017
Anticoagulation for the long-term treatment and prevention of thrombo-embolic diseases as well as for stroke prevention in atrial fibrillation (AF) has been accomplished by vitamin K antagonists for the last half century. Although effective under optimal
Braunwald, Eugene, Steffel, Jan
core  

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundElderly patients with atrial fibrillation are at higher risk of both ischemic and bleeding events compared to younger patients. In a prespecified analysis from the ENGAGE AF‐TIMI 48 trial, we evaluate clinical outcomes with edoxaban versus ...
Eri Toda Kato, Robert P. Giugliano, Christian T. Ruff, Yukihiro Koretsune, Takeshi Yamashita, Robert Gabor Kiss, Francesco Nordio, Sabina A. Murphy, Tetsuya Kimura, James Jin, Hans Lanz, Michele Mercuri, Eugene Braunwald, Elliott M. Antman   +13 more
doaj   +1 more source

Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants [PDF]

, 2016
Cancer patients are at major risk of developing Venous Thromboembolism (VTE), resulting in increased morbidity and economic burden. While a number of theories try to explain its pathophysiology, its risk stratification can be broadly done in cancer ...
Fatima Khalid, Hina Farooq, mouaz al-mallah, Shayan Qadir, Waqas Qureshi, Waseem Amjad, Zaid Alirhayim, Zeeshan Ali, Zeeshan Ali   +8 more
core   +3 more sources

Population pharmacokinetics and pharmacodynamics of edoxaban in pediatric patients

CPT: Pharmacometrics & Systems Pharmacology
Edoxaban is an orally active inhibitor of activated factor X (FXa). Population pharmacokinetic (PK) and pharmacodynamic (PD) analyses were performed to characterize the PK and PK–PD relationships of edoxaban in pediatric patients to identify the ...
Peng Zou, Akhilesh Atluri, Peter Chang, Michael Goedecke, Tarek A. Leil   +4 more
doaj   +1 more source

Surgical embolectomy for acute massive pulmonary embolism: state of the art [PDF]

, 2018
Massive pulmonary embolism (PE) is a severe condition that can potentially lead to death caused by right ventricular (RV) failure and the consequent cardiogenic shock.
De Bellis, Antonio, D’Abramo, Mizar, Frati, Giacomo, Greco, Ernesto, Iaccarino, Alessandra, Iovine, Elio, Saade, Wael, Schirone, Leonardo, Sciarretta, Sebastiano   +8 more
core   +1 more source

Viewpoint Stroke prevention in recent guidelines for the management of patients with atrial fibrillation: An appraisal. [PDF]

, 2017
Formal guidelines play an important role in disseminating the best available evidence knowledge and are expected to provide simple and practical recommendations for the most optimal management of patients with various conditions.
Camm, AJ, Chiang, C-E, Lip, GYH, Lundqvist, CB, Potpara, TS   +4 more
core   +3 more sources

Edoxaban in venous thromboembolism and stroke prevention: an appraisal

Vascular Health and Risk Management, 2016
Marco Proietti,1,2 Gregory YH Lip1,3 1University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK; 2Department of Internal Medicine and Medical Specialties, Sapienza-University of Rome, Rome, Italy; 3Aalborg Thrombosis ...
Proietti M, Lip GYH
doaj  

Edoxaban

Reactions Weekly, 2022
  +5 more sources

Prevalence, risk characteristics, and prediction of low-dose edoxaban treatment in hospitalized patients: a multicenter, observational cohort study

Frontiers in Pharmacology
BackgroundTreatment with a low-dose non-vitamin K antagonist oral anticoagulant (NOAC) is common among hospitalized patients, and a model to predict the need for such treatment would support individualized interventions.
Shujuan Zhao, Hengfen Dai, Jiaxin Chen, Ming Ni, Wenxing Peng, Xiaoyu Li, Fen Li, Boya Chen, Haixia Cai, Yinping Liu, Song Du   +10 more
doaj   +1 more source

Effectiveness and Safety of Dose-Specific DOACs in Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

Cardiovascular Therapeutics
Conclusions: This study found that all DOACs provided comparable or superior effectiveness and safety to warfarin. SD apixaban, SD edoxaban, and LD edoxaban achieved a favorable balance between preventing S/SE and MB risk.
Sang-Hyeon Oh, Seunghyun Cheon, Seo-Yong Choi, Young Seo Kim, Han-Gon Choi, Jee-Eun Chung   +5 more
doaj   +1 more source